These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 34450537)

  • 1. Targeted knockdown of Tim3 by short hairpin RNAs improves the function of anti-mesothelin CAR T cells.
    Jafarzadeh L; Masoumi E; Mirzaei HR; Alishah K; Fallah-Mehrjardi K; Khakpoor-Koosheh M; Rostamian H; Noorbakhsh F; Hadjati J
    Mol Immunol; 2021 Nov; 139():1-9. PubMed ID: 34450537
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Simultaneous targeting of Tim3 and A2a receptors modulates MSLN-CAR T cell antitumor function in a human cervical tumor xenograft model.
    Soltantoyeh T; Akbari B; Shahosseini Z; Mirzaei HR; Hadjati J
    Front Immunol; 2024; 15():1362904. PubMed ID: 38855110
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Disruption of adenosine 2A receptor improves the anti-tumor function of anti-mesothelin CAR T cells both in vitro and in vivo.
    Liu G; Zhang Q; Liu G; Li D; Zhang L; Gu Z; Tian H; Zhang Y; Tian X
    Exp Cell Res; 2021 Dec; 409(1):112886. PubMed ID: 34673000
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PD-1 silencing improves anti-tumor activities of human mesothelin-targeted CAR T cells.
    Liu G; Zhang Q; Li D; Zhang L; Gu Z; Liu J; Liu G; Yang M; Gu J; Cui X; Pan Y; Tian X
    Hum Immunol; 2021 Feb; 82(2):130-138. PubMed ID: 33341289
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of fludarabine and treosulfan on ovarian tumor cells and mesothelin chimeric antigen receptor T cells.
    El-Serafi I; Micallef Nilsson I; Moter A; Duan Z; Mattsson J; Magalhaes I
    Cancer Immunol Immunother; 2024 Jul; 73(9):163. PubMed ID: 38954005
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mesothelin-targeted CAR-T therapy combined with irinotecan for the treatment of solid cancer.
    Zhu Y; Zuo D; Wang K; Lan S; He H; Chen L; Chen X; Feng M
    J Cancer Res Clin Oncol; 2023 Nov; 149(16):15027-15038. PubMed ID: 37612388
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic and pharmacological targeting of A2a receptor improves function of anti-mesothelin CAR T cells.
    Masoumi E; Jafarzadeh L; Mirzaei HR; Alishah K; Fallah-Mehrjardi K; Rostamian H; Khakpoor-Koosheh M; Meshkani R; Noorbakhsh F; Hadjati J
    J Exp Clin Cancer Res; 2020 Mar; 39(1):49. PubMed ID: 32151275
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chemokine Receptor CCR2b Enhanced Anti-tumor Function of Chimeric Antigen Receptor T Cells Targeting Mesothelin in a Non-small-cell Lung Carcinoma Model.
    Wang Y; Wang J; Yang X; Yang J; Lu P; Zhao L; Li B; Pan H; Jiang Z; Shen X; Liang Z; Liang Y; Zhu H
    Front Immunol; 2021; 12():628906. PubMed ID: 33777013
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Construction and Functional Characterization of a Fully Human Anti-mesothelin Chimeric Antigen Receptor (CAR) Expressing T Cell.
    Jafarzadeh L; Masoumi E; Alishah K; Mirzaei HR; Jamali A; Fallah-Mehrjardi K; Rostamian H; Khakpoor-Koosheh M; Meshkani R; Noorbakhsh F; Hadjati J
    Iran J Allergy Asthma Immunol; 2020 Jun; 19(3):264-275. PubMed ID: 32615660
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of chimeric antigen receptor NK-92┬ácells to target mesothelin in ovarian cancer.
    Cao B; Liu M; Wang L; Liang B; Feng Y; Chen X; Shi Y; Zhang J; Ye X; Tian Y; Zhi C; Li J; Lian H; Wu Q; Zhang Z
    Biochem Biophys Res Commun; 2020 Mar; 524(1):96-102. PubMed ID: 31980173
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dominant-negative transforming growth factor-╬▓ receptor-armoured mesothelin-targeted chimeric antigen receptor T cells slow tumour growth in a mouse model of ovarian cancer.
    Li K; Xu J; Wang J; Lu C; Dai Y; Dai Q; Zhang W; Xu C; Wu S; Kang Y
    Cancer Immunol Immunother; 2023 Apr; 72(4):917-928. PubMed ID: 36166071
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic effiacy of T cells expressing chimeric antigen receptor derived from a mesothelin-specific scFv in orthotopic human pancreatic cancer animal models.
    Lee HH; Kim I; Kim UK; Choi SS; Kim TY; Lee D; Lee Y; Lee J; Jo J; Lee YT; Lee HJ; Kim SJ; Ahn JS
    Neoplasia; 2022 Feb; 24(2):98-108. PubMed ID: 34954452
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mesothelin CAR-T cells expressing tumor-targeted immunocytokine IL-12 yield durable efficacy and fewer side effects.
    Zhu Y; Wang K; Yue L; Zuo D; Sheng J; Lan S; Zhao Z; Dong S; Hu S; Chen X; Feng M
    Pharmacol Res; 2024 May; 203():107186. PubMed ID: 38641176
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mesothelin antigen density influences anti-mesothelin chimeric antigen receptor T cell cytotoxicity.
    Chu GJ; Bailey CG; Nagarajah R; Liang O; Metierre C; Sagnella SM; Castelletti L; Yeo D; Adelstein S; Rasko JEJ
    Cytotherapy; 2024 Apr; 26(4):325-333. PubMed ID: 38349311
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mesothelin-targeted CAR-T cell therapy for solid tumors.
    Klampatsa A; Dimou V; Albelda SM
    Expert Opin Biol Ther; 2021 Apr; 21(4):473-486. PubMed ID: 33176519
    [No Abstract]   [Full Text] [Related]  

  • 16. Mesothelin is a target of chimeric antigen receptor T cells for treating gastric cancer.
    Lv J; Zhao R; Wu D; Zheng D; Wu Z; Shi J; Wei X; Wu Q; Long Y; Lin S; Wang S; Wang Z; Li Y; Chen Y; He Q; Chen S; Yao H; Liu Z; Tang Z; Yao Y; Pei D; Liu P; Zhang X; Zhang Z; Cui S; Chen R; Li P
    J Hematol Oncol; 2019 Feb; 12(1):18. PubMed ID: 30777106
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mesothelin-specific CAR-T cell therapy that incorporates an HLA-gated safety mechanism selectively kills tumor cells.
    Tokatlian T; Asuelime GE; Mock JY; DiAndreth B; Sharma S; Toledo Warshaviak D; Daris ME; Bolanos K; Luna BL; Naradikian MS; Deshmukh K; Hamburger AE; Kamb A
    J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35091455
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Co-expression patterns of chimeric antigen receptor (CAR)-T cell target antigens in primary and recurrent ovarian cancer.
    Banville AC; Wouters MCA; Oberg AL; Goergen KM; Maurer MJ; Milne K; Ashkani J; Field E; Ghesquiere C; Jones SJM; Block MS; Nelson BH
    Gynecol Oncol; 2021 Feb; 160(2):520-529. PubMed ID: 33342620
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-mesothelin CAR-T immunotherapy in patients with ovarian cancer.
    Chen J; Hu J; Gu L; Ji F; Zhang F; Zhang M; Li J; Chen Z; Jiang L; Zhang Y; Shi R; Ma L; Jia S; Zhang Y; Zhang Q; Liang J; Yao S; Hu Z; Guo Z
    Cancer Immunol Immunother; 2023 Feb; 72(2):409-425. PubMed ID: 35925286
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic Targeting of Mesothelin with Chimeric Antigen Receptor T Cells in Acute Myeloid Leukemia.
    Le Q; Castro S; Tang T; Loeb AM; Hylkema T; McKay CN; Perkins L; Srivastava S; Call L; Smith J; Leonti A; Ries R; Pardo L; Loken MR; Correnti C; Fiorenza S; Turtle CJ; Riddell S; Tarlock K; Meshinchi S
    Clin Cancer Res; 2021 Oct; 27(20):5718-5730. PubMed ID: 34380639
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.